SM-88
Tyrosine metabolism inhibitor / A “dysfunctional” tyrosine mimetic. It is taken up by cancer cells and disrupts tyrosine-mediated metabolic pathways including synthesis of the important protein mucin-1 leading to oxidative stress.1 In clinical trials with melanin, phenytoin, and sirolimus (SMK therapy) for use in advanced metastatic cancer2, in combination with methoxsalen, phenytoin, and sirolimus (MPS therapy) for prostate cancer3, and as monotherapy for metastatic pancreatic cancer4. It is also an inhibitor of tyrosine hydroxylase resulting in a reduction of catecholamines and their metabolites.5
Biochemicals & reagents
30625-05-9
Racemetyrosine·HCl; DL-alpha-methyltyrosine·HCl
1) Lemberg et al. (2022), Clinical development of metabolic inhibitors for oncology; J. Clin. Invest., 132 e148550 2) Stega et al. (2020), A first-in-human study of the novel metabolism-based anti-cancer agent SM-88 in subjects with advanced metastatic cancer; Invest. New Drugs, 38 392 3) Gartell et al. (2021), Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer; Invest. New Drugs, 39 499 4) Noel et al. (2019), Phase II trial of SM-88 in patients with metastatic pancreatic cancer: Preliminary results of the first stage J. Clin. Oncol., 37 200 5) Brogden et al. (1981), alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use; Drugs, 21 81
RT
PATHWAY: Amino acid metabolism; Protein synthesis -- RESEARCH AREA: Oxidative stress -- DISEASE AREA: Cancer